Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model

The Ocular Surface(2021)10.1016/j.jtos.2021.03.009Source: DataRank Database

Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model is a research paper published in The Ocular Surface (2021). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.27)OA: greenTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Yu Chen ORCID,Rose Mathew ORCID,Victor L. Perez ORCID,Daniel R. Saban ORCID,Pali P. Singh

Live enrichment

PubMed:33812087 PMC:PMC8606044 OpenAlex:https://openalex.org/W3140737813

National Eye Institute

Grant: P30EY005722

National Eye Institute

Grant: R01 EY021798

NEI NIH HHS

Grant: R01 EY030906

National Institutes of Health

Novartis

FWCI

2.27

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8606044

publisherhttps://api.elsevier.com/content/article/PII:S1542012421000203?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542012421000203?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtos.2021.03.009

Fields of Study

Ocular Surface and Contact LensCorneal Surgery and TreatmentsAllergic Rhinitis and SensitizationAnimalsDry Eye SyndromesEyelid DiseasesHumansHypersensitivityImmunityLymphocyte Function-Associated Antigen-1Meibomian Gland DysfunctionMeibomian GlandsMicePhenylalanineSulfonesTears

MeSH Terms

Meibomian Gland DysfunctionAnimalsEyelid DiseasesHumansHypersensitivityImmunityMeibomian GlandsPhenylalanineSulfonesTearsDry Eye SyndromesLymphocyte Function-Associated Antigen-1Mice

Keywords

MedicineConjunctivaImmunologyImmune systemAllergic conjunctivitisAllergyOvalbuminNeutrophilsDry EyeMgdMeibomian Gland DysfunctionT(h)17Lifitegrast

Sustainable Development Goals

SDG 0: Good health and well-being

Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model

FAIR Checklist

Authors (5)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)